TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

AKEBIA

MetabolicCardiovascularGastroenterology
Pharma

AKEBIA is a pharmaceutical company focused on Metabolic, Cardiovascular, Gastroenterology. Key products include VAFSEO.

2024
Since
1
Drugs
-
Trials
1
Approved (2yr)

Key Drugs

VAFSEO
vadadustat
HIF-prolyl-4-hydroxylases 2 indications · 2024

Recent Activity

VAFSEO 2024-03-27
Type 1 - New Molecular Entity
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 40%
0 drugs Phase 2: 1
Cardiovascular 40%
0 drugs Phase 2: 1
Gastroenterology 20%
0 drugs Phase 1: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Merck big-pharma
Cardiovascular, Metabolic
QUAGEN specialty
Metabolic, Gastroenterology, Cardiovascular
Johnson & Johnson big-pharma
Cardiovascular, Metabolic
Bayer big-pharma
Cardiovascular, Metabolic
B BRAUN specialty
Metabolic, Cardiovascular